Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19807107 | 1.00 | KDM4E (0.57) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| SCHEMBL25015227 | 0.86 | KDM4E (0.53) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| SCHEMBL2226707 | 0.82 | KDM4E (0.57) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| SCHEMBL8741038 | 0.82 | KDM4E (0.57) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL5945948 | 0.81 | KDM4E (0.58) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL7615094 | 0.80 | KDM4E (0.57) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| SCHEMBL14615966 | 0.77 | KDM4E (0.35) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| SCHEMBL30323286 | 0.75 | KDM4E (0.53) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| SCHEMBL10062389 | 0.74 | KDM4E (0.56) | KDM4EHPGDALDH1A1HSD17B10MEN1 | |
| SCHEMBL12282726 | 0.74 | KDM4E (0.54) | KDM4EHPGDALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285572-A1 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC | 2023-09-14 | — | — | US | claimed |
| EP-4188433-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | Sepelo Therapeutics, LLC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| CN-117180287-B | Application of miltefosine in promoting bone formation and preventing and treating osteoporosis | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 2026-05-19 | — | — | CN | disclosed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-3448374-B1 | PREVENTION OF DRUG-INDUCED ATRIO-VENTRICULAR BLOCK | SIGNPATH PHARMA INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240398698-A1 | CONAZOLANTIFUNGAL KETOE IN SOLUTION OR SUSPENSION FOR USE IN THE HUMAN EAR | ALESSI DAVID (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240197716-A1 | TREATMENTS FOR CUSHING'S SYNDROME THAT DO NOT SIGNIFICANTLY AFFECT CARDIAC RHYTHMS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-06-20 | — | — | US | disclosed |
| CN-117651551-A | Use and method of using Nrf2 activators to enhance natural killer and/or T cell activity and/or survival | 成白血球细胞公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117180287-A | Application of miltefosine in promoting bone formation and preventing and treating osteoporosis | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 2023-12-08 | — | — | CN | disclosed |
| US-11806401-B2 | Prevention of drug-induced atrio-ventricular block | SIGNPATH PHARMA, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230285572-A1 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC | 2023-09-14 | — | — | US | disclosed |
| CN-116437961-A | Targeted delivery of therapeutic agents | 赛佩罗疗法有限责任公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116390734-A | Compounds and methods for enhancing T cell function | 中国科学院动物研究所 | 2023-07-04 | — | — | CN | disclosed |
| EP-4188433-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | Sepelo Therapeutics, LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-110678468-B | 5, 6-fused bicyclic compounds and compositions thereof for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197716-A1 | TREATMENTS FOR CUSHING'S SYNDROME THAT DO NOT SIGNIFICANTLY AFFECT CARDIAC RHYTHMS | KCNQ2, KCNQ1, KCNQ3 | KDM4E 344/4885HPGD 946/4885ALDH1A1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.